MedPath

Endoceutics, Inc.

Endoceutics, Inc. logo
πŸ‡§πŸ‡ͺBelgium
Ownership
Holding
Established
2006-01-01
Employees
101
Market Cap
-
Website
http://www.endoceutics.com

Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer

Phase 3
Withdrawn
Conditions
Vaginal Atrophy in Breast Cancer Patients
Interventions
First Posted Date
2018-11-14
Last Posted Date
2020-07-31
Lead Sponsor
EndoCeutics Inc.
Registration Number
NCT03740945

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study

Phase 3
Withdrawn
Conditions
Hypoactive Sexual Desire Disorder (HSDD)
Interventions
First Posted Date
2018-08-07
Last Posted Date
2020-07-31
Lead Sponsor
EndoCeutics Inc.
Registration Number
NCT03619005
Locations
πŸ‡ΊπŸ‡Έ

Endoceutics site # 91, Savannah, Georgia, United States

πŸ‡ΊπŸ‡Έ

Endoceutics site # 20, New York, New York, United States

πŸ‡ΊπŸ‡Έ

Endoceutics site # 106, Huntsville, Alabama, United States

and more 7 locations

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

Phase 3
Completed
Conditions
Hypoactive Sexual Desire Disorder
Interventions
First Posted Date
2017-09-19
Last Posted Date
2021-04-09
Lead Sponsor
EndoCeutics Inc.
Target Recruit Count
653
Registration Number
NCT03287232
Locations
πŸ‡ΊπŸ‡Έ

Endoceutics site # 106, Huntsville, Alabama, United States

πŸ‡ΊπŸ‡Έ

Endoceutics site # 104, Mobile, Alabama, United States

πŸ‡ΊπŸ‡Έ

Endoceutics site # 108, Berkeley, California, United States

and more 66 locations

Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause

Phase 3
Completed
Conditions
Vaginal Atrophy
Interventions
First Posted Date
2013-12-17
Last Posted Date
2017-06-01
Lead Sponsor
EndoCeutics Inc.
Target Recruit Count
558
Registration Number
NCT02013544
Locations
πŸ‡¨πŸ‡¦

EndoCeutics site # 69, Corunna, Ontario, Canada

πŸ‡¨πŸ‡¦

EndoCeutics site # 77, Quebec City, Quebec, Canada

πŸ‡¨πŸ‡¦

EndoCeutics site # 04, Drummondville, Quebec, Canada

and more 35 locations

Topical DHEA Against Vaginal Atrophy

Phase 3
Completed
Conditions
Vaginal Atrophy
Interventions
First Posted Date
2013-05-03
Last Posted Date
2017-08-29
Lead Sponsor
EndoCeutics Inc.
Target Recruit Count
218
Registration Number
NCT01846442
Locations
πŸ‡ΊπŸ‡Έ

EndoCeutics site # 05, Cleveland, Ohio, United States

πŸ‡ΊπŸ‡Έ

EndoCeutics site # 03, Norfolk, Virginia, United States

πŸ‡¨πŸ‡¦

EndoCeutics site # 10, Montreal, Quebec, Canada

and more 5 locations

Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women

Phase 3
Completed
Conditions
Vasomotor Symptoms
Hot Flushes
Interventions
First Posted Date
2011-10-14
Last Posted Date
2013-12-11
Lead Sponsor
EndoCeutics Inc.
Target Recruit Count
238
Registration Number
NCT01452373
Locations
πŸ‡¨πŸ‡¦

EndoCeutics site # 04, Drummondville, Quebec, Canada

πŸ‡¨πŸ‡¦

EndoCeutics site # 69, Corunna, Ontario, Canada

πŸ‡¨πŸ‡¦

EndoCeutics site # 71, London, Ontario, Canada

and more 12 locations

Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy

Phase 3
Completed
Conditions
Vaginal Atrophy
Interventions
Drug: Placebo
First Posted Date
2011-05-24
Last Posted Date
2017-06-12
Lead Sponsor
EndoCeutics Inc.
Target Recruit Count
450
Registration Number
NCT01358760
Locations
πŸ‡ΊπŸ‡Έ

EndoCeutics site # 66, Danbury, Connecticut, United States

πŸ‡ΊπŸ‡Έ

EndoCeutics site # 27, Baltimore, Maryland, United States

πŸ‡ΊπŸ‡Έ

EndoCeutics site # 15, Columbus, Ohio, United States

and more 39 locations

DHEA Against Vaginal Atrophy - Safety Study of 12 Months

Phase 3
Completed
Conditions
Vaginal Atrophy
Interventions
First Posted Date
2010-12-08
Last Posted Date
2017-10-18
Lead Sponsor
EndoCeutics Inc.
Target Recruit Count
530
Registration Number
NCT01256671
Locations
πŸ‡ΊπŸ‡Έ

EndoCeutics site # 25, Lincoln, Nebraska, United States

πŸ‡ΊπŸ‡Έ

EndoCeutics site # 09, West Jordan, Utah, United States

πŸ‡¨πŸ‡¦

EndoCeutics site # 13, Calgary, Alberta, Canada

and more 38 locations

DHEA Against Vaginal Atrophy - 3-Month Efficacy Study

Phase 3
Completed
Conditions
Vaginal Atrophy
Interventions
Drug: Placebo
First Posted Date
2010-12-08
Last Posted Date
2017-06-26
Lead Sponsor
EndoCeutics Inc.
Target Recruit Count
255
Registration Number
NCT01256684
Locations
πŸ‡ΊπŸ‡Έ

EndoCeutics site # 21, Sacramento, California, United States

πŸ‡ΊπŸ‡Έ

EndoCeutics site # 22, Kalamazoo, Michigan, United States

πŸ‡ΊπŸ‡Έ

EndoCeutics site # 10, Meridian, Idaho, United States

and more 30 locations
Β© Copyright 2025. All Rights Reserved by MedPath